Tumor markers accuracy
DOI:
https://doi.org/10.32635/2176-9745.RBC.1998v44n3.2813Keywords:
Tumor MarkersAbstract
Considering the increasing number ofthe so callediumox markers and its systematic use in the medicai practice, an assessment was made through Medline© 1995 at the Central Library of the Brazilian National Cancer Institute - INCA, and 95 abstracts, published from 1995 to April 1997 were reviewed. It was noted that tumor validity is higher for some types of tumor and for some prognostic factors; that few of them are of real clinical utility, either for prevention, diagnosis or prognosis, as most of them are only significant when there is some signs or symptoms of the disease; that most of the studies are somewhat repeated, as same markers are assessed in different tumors; and there are studies which refer tofew cases, or very few, and because of this the results are inconsistent. In this article, tumor markers are classified by types (genes, genetic expressions, circulating substances, intracellular substances, cellular membrane receptors and cell proliferation indices) and according to their purposes (risk assessment, screening, differential diagnosis, staging, assessment of therapeutic efficacy, post treatment follow-up, and prognosis) and are correlated with the tumor(s) in which they were analyzed. It is presented three groups of validation criteria (statistic, biomedical and uses) and it is summarized, from 16 other bibliographic references, the clinicai utility of breast cancer markers [DNA, Phase S, DNA index, C-erbB-2 (HER-2/neu), p53 e CAT-D, CAI 5.3 and CEA - non-valid; hormonal receptors for indication ofadjuvant orpalliative hormoniotherapy - valid]; colo-rectal cancer markers (LASA, CA 19.9, DNA index, phase S, P53 and ras - non-valid; CEA for staging and surgical planning, and for postoperative follow up - a dosage series every 2-3 months for two years, if one suspects of liver metastasis in surgical stages II and III - valid) and of prostate cancer (PSA useful for detection, but associated with rectum hand examination in males over 40-50 years ofage, as indicatives of the need of more accurate studies, and for posttreatmentf ollow up). It is out of the question the utility of alpha-fetoprotein (aFP) and human chorionic gonadotropin (HCG), for staging, assessment of the therapeutic response and posttreatment follow up of cancer of testis (aEP and HCG) and of gestational trophoblastic disease (HCG). There is also no doubt that identifying cell differentiation markers are valid for pathological diagnosis of leukemias and lymphomas. From this study, five dilemmas are identified: 1) absence of signs and symptoms versus a positive tumor marker; 2) detection ofasymptomatic relapsevexsus quality and length ofsurvival; 3) non-malignant cause versus marker increase; 4) false-positive result versus treatment; and 5) low risk of tumor progression versus treatment. It is concluded that, except for utility established for diagnosis, posttreatment follow-up or prognosis for some types of cancer, the physician must know not only tumor markers and their abbreviations, but also their accuracy and to have an opinion, criteria and method in their clinical use.
Downloads
References
Stridsberg, M.- The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. J Med Sci, 100(3): 169-99,1995. DOI: https://doi.org/10.3109/03009739509178905
Negri,S.;Bonzanini,M.;Togni,R.;Castelli, P.; Della-Palma, P.; Fiaccavento, S. – Fine needie aspiration ofmyofibroblastoma of the breast. Case report, Pathologica,87(6):719-22,1995 Dec.
Boticelli, A.R.; Marandola, P.; Jallous, H.; Vicini,D.; Migaldi,M.; Speroni,A.; Mirando, P. - Quantitative and qualitative AgNORs rates of prostate cancer on needie core bipsies: multicentric study. Pathologica,87(6): 624-30,1995 Dec.
Ronai, Z.; Minamoto, T.; Butier, R.; Tobi,M.; Luo,F.Q.;Zang,E.;Esumi,H.; Sugimura,T. - Sampling method as a key factor in identifying K-ras oncogene mutations in pre-neoplastic colorectal lesions. Cancer-Detect-Prev, 19(6):512-7,I995.
Spiridonidis, C.H.; Laufman, L.R.; Stydnicki, K.A.,et al.- Decline of posttreatment tumor marker leveis after therapy of nonsmall cell lung cancer. A useful outcome predictor. Cancer,75(7): 1586-93, 1995 Aprl. DOI: https://doi.org/10.1002/1097-0142(19950401)75:7<1586::AID-CNCR2820750706>3.0.CO;2-K
Kolles, H.; Niedermayer, I.; Schimitt, C., et al. - Triple approach for diagnosis and grading of meningiomas: histology,morphometry of Ki-67/Feulgen stainings, and cytogenetics. ActaNeurochir.,137(3-4): 174-81, Wien. 1995. DOI: https://doi.org/10.1007/BF02187190
Kawamoto,H.; Uozumi,T.; Kawamoto,K.; Arita, K.; Yano,T.; Hirohata,T.- Analysis of the growth rate and cavernous sinus in vasion ofpituitary adenomas. Acta Neurochir, 1369 (1-2): 37-43, Wien. 1995. DOI: https://doi.org/10.1007/BF01411433
Devine, P.L.; Walsh, M.D.; McGuckin, M.A.; Quin, R.J.; Hohn,B.G.; Clague, A.; Samaratunga,H.- Prostate-specific antigen (PSA)and cancer-association serum antigen(CASA)in distinguishing benign and malignant prostate disease. Int J Biol Markers, 10(4):221-5, 19950ct-Dec. DOI: https://doi.org/10.1177/172460089501000406
Murray, A.; Robertson, J.F.; Price, M.R.- Analysis ofthe temporal compressibility of breast tumor marker assays: development of a “near patient” assay. Int J Biol Markers, 10 (4):200-5,1995 Oct-Dec. DOI: https://doi.org/10.1177/172460089501000402
Lagana, A.; Pardo-Martinez, B.; Marino,A.; Fago,G.; Bizzarri, M.- Determination of serum total lipid and free N-acetyIneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of free N-acetylneuraminic acid as tumor marker. Clin Chim Acta, 243(2): 165-79, 1995 Dec 29. DOI: https://doi.org/10.1016/0009-8981(95)06165-7
Kressner, U.; Lindmark, G.; Gerdin, B.; PahIman, L.; Glimelius,B.- Heterogeneity in proliferation markers in colorectal cancer. Anticancer Res, 15(6B):2755-61, l995Nov- Dec.
Pasanen, P.A.; Eskelinen, M.; Partanen, K.; Pikkarainen, P.; Penttila, I.; Alhava,E.- Multivariate analysis of six serum tumor markers (CEA,CA 50,CA 242,TPA,TPS,TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res, 15(6B): 1731-7, 1995 Nov-Dec.
Veronese, S.M.; Maisano, C.; Scibilia, J.-Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breastcancer. Anticancer Res, 15(6B):2717-22,1995Nov-Dec.
Lundin,J.;Nordling,S.; von Boguslawsky,K.; Roberts,P.J.;Haglund,C.- Prognostic value of Ki-67expression,ploidy and S-phasefraction in patients with pancreatic cancer. Anticancer Res,15(6B):2659-68,1995Nov-Dec.
Roux,F.J.; Lantueejoul, S.; Brambilla, E.; Brambilla,C.-Mucinous cystadenoma of the lung. Cancer, 76(9); 1540-4, Nov 1. DOI: https://doi.org/10.1002/1097-0142(19951101)76:9<1540::AID-CNCR2820760907>3.0.CO;2-Z
Gaarenstroom, K.N.; Bronfrer, J.M.; Kenter, G.G.; Korse,C.M.;Hart, A.A.;Trimbos,J.B.; Helmerhorst,T.J.-Clinicai value of pretreatment serum Cyfra 21-1,tissue polypeptide antigen, and squamous cellcarcinoma antigen leveis in patients with cervicalcâncer.Câncer,76(5):807- 13,1995Sepl. DOI: https://doi.org/10.1002/1097-0142(19950901)76:5<807::AID-CNCR2820760515>3.0.CO;2-M
Tellechea, O.; Reis, J.P.; Ilheu, O.; Baptista, A.P.- Dermal cylindroma. Am immunohistochemical study ofthirteen cases. Am J Dermatopathol, 17(3): 260-5,1995 Jun. DOI: https://doi.org/10.1097/00000372-199506000-00008
Nakasu,S.;Nakajima,M.;Matsumura,K.;Nakasu,Y.;Handa,J.- Meningioma: proliferating potential and clinicoradiological features. Neurosurgery,37(6): 1049-55,1995Dec. DOI: https://doi.org/10.1097/00006123-199512000-00003
Lagana,A.;Pardo-Martinez,B.;Marino,A.; Fago,G.;Bizzarri,M.- Correlation of sérum sialic acid fractions as markers for carcinoma oftheuterinecervix. Anticancer Res,15(5B): 2341-6,1995 Sep-Oct.
Paraf,F.; Gogusev,J.; Chretien,Y.;Droz,D. - Expression ofbcl-1 oncoprotein in renal cell tumors.J Pathol, 177(3);247-52,1995 Nov. DOI: https://doi.org/10.1002/path.1711770306
Song,Y.;Yao,G.;Fu,C.- A study of immunoactivity ofretinal S-antigen in retinoblastoma. YenKo Hsueh Pao,1 l(l): 22-5, 1995 Mar.
Healy,E.;Angus,B.;Lawrence,C.M.;Rees, J.L. - Prognostic value of Ki67 antigen expression in basal cell carcinomas. BrJDer- matol, 133(5):737-41,1995 Nov. DOI: https://doi.org/10.1111/j.1365-2133.1995.tb02748.x
Palestro,G.;Pich,A.;Chiusa,L.- Biological heterogeneity ofdiffuse mixed small and large non-Hodgkin’s lymphomas assessed by DNA flow cytometry and Ki67.Leuk lymphoma,19(5-6):467-72,1995Nov. DOI: https://doi.org/10.3109/10428199509112206
Patel,P.S.;Raval,G.N.;Rawal,R.M.;Patel, G.H.;Balar,D.B.;Shah,P.M.;Patel,D.D.-Neoplasma,42(5):271-4,1995.
Choong,P.F.; Akerman,M.;Willen,H.;An- dersson, C.; Gustafson, P.; Alvegard, T.;Rydholm,A.- Expression of proliferating cell nuclear antigen (PCNA)and Ki-67 in softtissue sarcoma. Is prognostic significance histotype-specific? APMIS, 103(11); 797-805, 1995 Nov DOI: https://doi.org/10.1111/j.1699-0463.1995.tb01437.x
Russel-Jones, R.; Orchard, G.; Zelger, B.; Wilson-Jones, E. - Immunostaining for CDS 1 and CD34 in Kaposi sarcoma. J Clin Pathol,48(11): 1011-6,1995 Nov. DOI: https://doi.org/10.1136/jcp.48.11.1011
vanderGaast,A.; Kok,T.C.;Kho,G.S.;Blijenberg,B.G.;Splinter,T.A.- Disease monitoring by the tumor markers cyfra 21.1 and TPA in patients with non-small cell lung cancer. EurJ Câncer,31 A(11): 1790-3, 1995 Oct. DOI: https://doi.org/10.1016/0959-8049(95)00342-G
Davis,R.L.; Onda,K.;Shubuya,M.;Lamborn,K.;Hoshino,T.- Proliferation markers ingliomas; acomparison of BUDR,Ki-67, and MIB-1.J Neurooncol,24(1):9-12,1995. DOI: https://doi.org/10.1007/BF01052651
Buccheri,G.;Eerrigno,D.- Monitoringlung cancer with tissue polypeptide antigen: na ancillary,profitableserum testto evaluate treatment response and posttreatment disease status. Lung Cancer, 13(2): 155-68,1995 Oct.
Buccheri,G.;Eerrigno,D.- Monitoring lung cancer with tissue polypeptide antigen: na ancillary,profitableserum testto evaluate treatment response and posttreatment disease status. Lung Cancer, 13(2): 155-68,1995 Oct. DOI: https://doi.org/10.1016/0169-5002(95)00491-2
Willett,C.G.;Daly,W.J.;Warshaw,A.L.CA 19.9 is an index ofresponse to neoadjunctive chemoradiation therapy in pancreatic cancer. Am JSurg, 172(4);350-2,1996 Oct. DOI: https://doi.org/10.1016/S0002-9610(97)89547-5
Bem Ezra, J.M., Kornstein,M.J.- Antibody NCL-CD5 fails to detect neoplastic CD5+ cells in paraffin sections. Am J Clin Pathol, 106(3):273-4,1996Sep.(Comment) DOI: https://doi.org/10.1093/ajcp/106.3.370
Pectasides, D.; Pavlidis, N.; Gogou,L.; Antoniou,F.;Nicolaides,C.;Tsikalakis,D.- Clinical value of CA 15.3,mucin-like carcinoma-associated antigen, tumor polypeptide antigen,and carcinoembryonic antigen in monitoring early breastcâncer patients. Am J Clin Oncl, 19(5):459-64,19960ct. DOI: https://doi.org/10.1097/00000421-199610000-00007
Buchfelder,M.;Fahlbusch,R.;Adams,E.F.; Kiesewetter,F.; Thierauf,P.- Proliferation parameters for pituitary adenomas. Acta NeurochirSuppl,65: 18-21, Wien. 1996. DOI: https://doi.org/10.1007/978-3-7091-9450-8_7
Ogden, G.R.; Leigh, I.; Chisholm, D.M.; Cowpe, J.G.; Lane, E.B.-Exfoliative cytology of normal oral mucosa. Assessing the basal cell keratin phenotype. Acta Cytol,40(5):933-6,1996Sep-Oct. DOI: https://doi.org/10.1159/000334004
Nesi, G.; Vezzosi, V.; Amorosi, A.; Menghetti,I.; Selli,C.D.- Paraganglioma of the urinary bladder. Urol Int,56(4): 250-3, 1996. DOI: https://doi.org/10.1159/000282853
Ambrosiani, L.; Bellone, S.; Betto, F.S., et al. - Rhabdomyosarcoma presenting as acute hematologic malignancy: case report and review of the literature. Tumori,82(4):408-12,1996Jul-Aug. DOI: https://doi.org/10.1177/030089169608200424
Parki,Y.K.;Yang,M.FI.;Park,H.R.-The impact of osteonectin for differential diagnosis of osteogenic bone tumors:an immunohistochemical and in situ hybridization approach. SkeletalRadiol,25(l): 13-7, 1996 Jan DOI: https://doi.org/10.1007/s002560050025
Dhingra,K.;Hortobagyi,G.N.- Critical evaluation of prognostic factors. Semin Oncol, 23(4): 436-45, 1996 Aug.
Dorsey,B.V.;Benjamin,L.E.; Rauscher,E. 3rd; Klencke,B.;Venook,A.P.;Warren,R.S.; Weidner,N.- Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile. Mod Pathol, 9(6): 703-9, 1996 Jun. DOI: https://doi.org/10.1097/00125480-199611000-00022
Joshi, M.G.; Lee, A.K,; Pedersen, C.A.; Schnitt,S.;Camus,M.G.;Hughes,K.S.-The role ofimmunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions ofthe breast. Mod Pathol, 9(1): 57-62,1996 Jan.
Tomita,T.- DNA ploidy and proliferating cell nuclear antigen in islet cell tumors. Pancreas, 12(1): 36-47,1996 Jan. DOI: https://doi.org/10.1097/00006676-199601000-00005
Watanabe,H.;Sawabu,N.;Songur,Y.,et al. - Detection ofK-ras point mutations at codon 12 in pure pancreaticjuice for the diagnosis ofpancreatic cancer by PCR-RFLP analysis. Pancreas, 12(1): 18-24, 1996 Jan. DOI: https://doi.org/10.1097/00006676-199601000-00003
Scott,I.U.;Tabenbaum,M.;Rubin,D.;Lores, E.- Solitary fibroustumor ofthe lacrimal gland fossa.Ophthalmology, 103(10): 1613-8,1996 oct. DOI: https://doi.org/10.1016/S0161-6420(96)30455-7
Gershenson,D.M.;Tortolero-Luna,G.;Malpica,A.;Baker,V.V.;Whittaker,L.;Johnson, E.;Eollen-Mitchel1,M.- Ovarian intraepithelial neoplasia and ovarian câncer.Obstet Gynecol ClinNorthAm, 13(2): 475-543, 1996 Jun.
Levenback,C.F.;Tortolero-Luna,G.;Pandey, D.K.,etal.-Uterine sarcoma. Obstet Gynecol Clin North Am, 23(2): 457-73, 1996 Jun.
Burke, T.W.; Tortorelo-Luna, G.; Malpica, A.; Baker, V. V.; Whittaker, L.; Johnson, E.; Follen-Mitchell, M. - Endometrial hypeiplasia and endometrial cancer. Obstet Gy necol Clin North Am,23(2):4ll-56, 1996 Jun.
Morris,M.;Tortorelo-Luna, G.;Malpica, A.; Baker, V.V.; Cook, E.; Johnson, E.; FollenMitchell, M. - Cervical intraepithelial neoplasia and cervical cancer. Obstet Gynecol Clin North Am, 23(2): 347-410,1996 Jun.
Edwards,C.L.; Tortorelo-Luna,G.;Linares, A.C.; Malpica, A.; Baker, V.V.; Cook, E.; Johnson, E.; Follen-Mitchell, M.- Vul var intraepithelial neoplasia and cancer vulvar cancer. Obstet Gynecol Clin North Am, 23(2): 295-324, 1996 Jun.
Ruelle, A.;Tunesi,G.; Andrioli, G.-Spinal meningeal melanocytoma. Case report and analysis of diagnostic criteria. Neurosurg Rev, 19(1): 39-42, 1996. DOI: https://doi.org/10.1007/BF00346608
Ramdial, P.K.; Nadvi, S. - An unusual cause of protoptosis: orbital solitary fibrous tumor: case report Neurosurgery, 38(5): 1040-3, 1996 May. DOI: https://doi.org/10.1097/00006123-199605000-00037
Berzinec, P.;Zuffova, H.; Letkovicova, M.; Arpasova,M.- Serum tumor markerCYFRA 21 -1 in the diagnosis of squamous cell lung cancer - comparison with CEA. Neoplasma, 43(3): 159-61,1996. DOI: https://doi.org/10.1016/S0169-5002(97)80217-6
Wojciechowska-Lacka,A.;Matecka-Nowak, M.; Adamiak, E.; Lacki, J.K.; Cerkaska Gluszak, B. - Serum leveis of interleukin-10 and interleukin-6 in patients with lung câncer. Neoplasma, 43(3): 155-8, 1996.
Kovarik, J.; Skry, G.D.; Mikel, J.; Svoboda, V.H. -Changes of Ki67 indexofvarious tumors during radiation therapy. Neoplasma, 43(2): 89-92,1996.
Tsai, S.C.; Kao,C.H., Wang, S.J. - Study of a new tumor marker, CYFRA 21 -1, in squamous cell carcinoma of the cervix, and com parison with squamous cell carcinoma antigen. Neoplasma, 43(1): 27-9, 1996.
Kadayifci, A.; Simsek, H.; Savas, M.C.; Toppare, M. - Serum tumormarkers in chronic liverdisease. Neoplasma, 43(1): 17-21,1996.
Jacob,R.;Welkoborsky,H.J.;Mann,W.J.;Hofken,F.; Dienes, H.P.; Freije, J.E. - Hetero-geneity of squamous cell carcinomas ot the head and neck - analysis of tumor biologic factors and proliferation rates. Laryngoscope, 106(9 Pt 1): 1 170-5,1996 Sep. DOI: https://doi.org/10.1097/00005537-199609000-00023
Takeuchi, S.; Arai, K.;Saitoh,H.; Yoshida, K,; Miura, M. - Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. JUrol, 156(5): 1691-5, 1996 Nov. DOI: https://doi.org/10.1016/S0022-5347(01)65484-3
Bauer, J.J.;Sesterhenn,I.A.;Mostofi,F.K.; McLeod, D.G.; Srivastava, S.; Moul, J.W. - Elevated leveis of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate câncer. J Urol, 156(4): 1511-6, 1996 Oct. DOI: https://doi.org/10.1016/S0022-5347(01)65641-6
Carpinito, G.A.; Stadler, W.M.; Briggman, J.V., et al. - Urinary nuclearmatrix protein as amarker for transi tional cell carcinoma of the urinary tract. JUrol, 156(4): 1280-5,1996 oct. DOI: https://doi.org/10.1016/S0022-5347(01)65569-1
Hayes,D.F.;Bast,R.C.;Desch,C.E.,etal.-Tumor marker utility grading system: a framework to evaluateclinical utility of tumor markers. J Nat Cancerinst, 88(20): 1456-66,19960ct 16. DOI: https://doi.org/10.1093/jnci/88.20.1456
Prentice, R.L. - Tumor markerutility grading System. JNat Câncer Inst, 88(20): 1419-20, 1996 Oct 16. (Editorial: comment) DOI: https://doi.org/10.1093/jnci/88.20.1424
Santini,D.;Ceccarelli,C.;Taffurelli,M.;Pileri, S.; Morrano, D. - Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol, 179(4): 386-91,1996 Aug. DOI: https://doi.org/10.1002/(SICI)1096-9896(199608)179:4<386::AID-PATH631>3.0.CO;2-V
Rajkumar, T.; Stamp, G.W.; Pandha, H.S.; Waxman, J.; Gullick, W.J. - Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder câncer. J Pathol, 179(4): 386-91. DOI: https://doi.org/10.1002/(SICI)1096-9896(199608)179:4<381::AID-PATH603>3.0.CO;2-X
Sanjuan, X.; Fernandez, P.L.;Miquel, R., et al. - Over expression of the 67-kD laminin receptor correlates with tumor progression in human colorectal carcinomas. J Pathol, 179(4): 376-80, 1996 Aug. DOI: https://doi.org/10.1002/(SICI)1096-9896(199608)179:4<376::AID-PATH591>3.0.CO;2-V
Dabelsteen, E. - Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol, 179(4): 358-69,1996 Aug. DOI: https://doi.org/10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T
Yoshida,J.;Chiji,wa,K,;ShimuraJÍ.,Yama- guchi, K.; Kinukawa, N.; Honda, H.; Tanaka, M. - Xanthogranulomatous cholecystitis versus gallbladder cancer: clinical differentiating factors. AmSurg,63(4): 367-71, 1997 Apr.
Velanovich, V. - Biologic tumor markers, lymph node status, and decision about adjuvant chemotherapy for breast cancer. Am Surg,63(4): 330-3,1997 Apr.
Reintgen,D.S.;Conrad, A.J.-Detection of occult melanoma cells in sentinel lymph nodes and blood. Semin Oncol, 24( 1 Suppl 4): Sll-5,1997Feb.
Arai, Y.; Yoshiki,T.; Yoshida, O. -c-erB2 oncoprotein: apotential biomarkerof advanced prostate cancer. Prostate, 30(3): 195-201, 1997Febl5. DOI: https://doi.org/10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L
Skomedal,H.;Kristensen,G.B.;Abeler,V.M.; Borresen-Dale, A.L.;Trope, C.; Holm, R. - TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I car cinomas. JPathol, 181(2): 158-65,1997Feb. DOI: https://doi.org/10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8
McNicol, A.M.; Nolan, C.E.; Struthers, A.J.; Farquharson, M. A.; Hermans, J.; Haak, H.R. - Expression of p53 in adrenocortical tumours: clinicopathological correlations. J Pathol, 181(2): 146-52, 1997 Feb. DOI: https://doi.org/10.1002/(SICI)1096-9896(199702)181:2<146::AID-PATH744>3.0.CO;2-7
Wamil,B.D.;Thurman, G.B.; Sundell,H.W., et al. - Soluble E-selectin in cancer patients as a marker of therapeutic efficacy ofCM 101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J Cancer ResClin Oncol, 123(3): 173-9,1997. DOI: https://doi.org/10.1007/s004320050046
Yamanaka, N.; Tanaka, T.; Tanaka, W., et al. - Correlation of hepatitis virus serologic status with clinico pathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Câncer, 79(8): 1509-15, 1997 Aprl 5. DOI: https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1509::AID-CNCR10>3.0.CO;2-1
Pompili,M.;Rapacchini,G.L.;deLuca,F.,et al. - Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer, 79(8): 1501-8,1997 Apr 15. DOI: https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1501::AID-CNCR9>3.0.CO;2-D
Schauenstein,E.;Rabl,H.;Steinschifter,W.; Hirschmann, C.; Estelberg, W.; Schauenstein, K. - Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue. Cancer, 79(8): 1482-6,1997 Apr 15. DOI: https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1482::AID-CNCR6>3.0.CO;2-D
Dabare, A.A.;Nouri, A.M.;Reynard, J.M.; Killala, S.; Oliver, R.T. - A new approach using tissue alkaline phosphatase activity to identify early testicular cancer. Br J Urol, 79(3): 455-60,1997 Mar. DOI: https://doi.org/10.1046/j.1464-410X.1997.03526.x
Radich, J.; Gehly, G.;Lee, A., etal. -Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood, 89(7): 2602-9,1997 Aprl. DOI: https://doi.org/10.1182/blood.V89.7.2602
Ng,M.H.;Chung, Y.F.;Lo, K.W.;Lee, J.C.; Huang, D.P. - Frequent hypermethylation of p 16 and p 15 genes in multiple myeloma. Blood, 89(7): 2500-6, 1997 Aprl. DOI: https://doi.org/10.1182/blood.V89.7.2500
Okada, H.; Gotoh, A.; Ogawa, T.; Arakawa, S.; Ohbayashi, C.; Kamidono, S. - Two cases of small cell carcinoma of the prostate. Scand JUrol Nephrol, 30(6): 503-8,1996 Dec. DOI: https://doi.org/10.3109/00365599609182334
Cacic,M.;Petrovic,D.;Tentor,D.;Hutinec, Z.; Jelasic, D. - Cystosarcoma phyloides of the prostate. Scand J Urol Nephrol 30(6): 501-6,1996 Dec. DOI: https://doi.org/10.3109/00365599609182333
Hintsa, A.;Lindell,O.;Heikkila,P.-Neuro-fibromatosis of the bladder. Scand J Urol Nephrol, 30(6): 497-9,1996 Dec. DOI: https://doi.org/10.3109/00365599609182332
Vargas,M.P.;Vargas,H.I.;Kleiner,D.E.;Merino, M. J. -Theroleofprognostic maiLei-s (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol, 10(1): 12-7, 1997 Jan.
DeFlora,S.,Camoirano, A.;Bagnasco,M.,et al. - Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials. J Cell Biochem Suppl, 25: 92-8, 1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<92::AID-JCB13>3.0.CO;2-P
Kensler, T.W.; Groopman, J.D. - Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. JCell Biochem Suppl, 25:85-91,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<85::AID-JCB12>3.0.CO;2-M
Spitz, M.R.; Wu, X.; Jiang, H.; Hsu, T.C. - Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl, 25:80- 4,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<80::AID-JCB11>3.0.CO;2-R
Mark, S.D. - Defining and analysing cohorts using molecular marker sof cancer risk. J Cell Biochem Suppl, 25:69-79,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<69::AID-JCB10>3.0.CO;2-I
Mooney, L. A., Perera, F.P. - Application of molecular epidemiology to lung câncer chemoprevention. J Cell Biochem Suppl, 25:63- 8,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<63::AID-JCB9>3.0.CO;2-0
Weinstein.I.B.-Relevance of cyclin Dl and other molecular markers to câncer chemo-prevention. J Cell Biochem Suppl, 25: 23- 8,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<23::AID-JCB3>3.0.CO;2-4
Hemstreet,G.P. 3rd; Rao, J.;Hurst, R.E.,et al. - G-actin as a risk factor and modulatable end point for cancer chemoprevention trials. J Cell Biochem Suppl, 25: 197-204,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<197::AID-JCB28>3.0.CO;2-K
Mao, L. - Genetic alterations as clonal markers for bladder cancer detection in urine. J Cell Biochem Suppl, 25: 191-6,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<191::AID-JCB27>3.0.CO;2-Q
Bagg, A.; Cossman, J.- Molecular genetic biomarkers in hematological malignancies. J Cell Biochem Suppl, 25:165-71,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<165::AID-JCB23>3.0.CO;2-M
Baron, J. A. - Large bo wel adenomas: markers of risk and endpoints. J Cell Biochem Suppl, 25:142-8,1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<142::AID-JCB20>3.0.CO;2-P
Neyfield, S.G. - Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast câncer. J Cell Biochem Suppl, 25: 123-30, 1996. DOI: https://doi.org/10.1002/(SICI)1097-4644(1996)25+<123::AID-JCB17>3.0.CO;2-P
Brugal, G. - Quantitative microscopy and tumor cell proliferation. Bull Câncer Paris, 82 (Suppl 5):51 1s-5]7s, 1995 Dec.
Hayes, D.F. - When Isa Tumor Marker Ready for Prime Time?The Tumor Marker Utility Grading Scale. In: American Society of Clinical Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco; 206-12,1997.
Gadelha,M.I.P.;Minian, A.;Coutinho,E.; GouveiaFilho, J.J. - ValidadedoCA 15.3 para o seguimento de pacientes tratadas de cancer de mama. Rev Bras Cancerol, 79-85, 1994.
Hayes, D.F.- Serum (Circulating) Tumor Markers for Breast Câncer. In: American Society of Clinical Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco;228-33, 1997.
Ravdin, P.M.- Prognostic Factors in Breast Cancer. In: American Society of Clinicai Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco; 217-27, 1997.
Douglas, W.B. - Management of the Tumor Marker-Positi ve, Disease-Negati ve Patient. In: American Society of Clinicai Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco; 100-1, 1997.
Markman, M.- Management of CA-125 Elevation in a Patient with O varian Cancer but without other Clinical Evidence of Disease. In: American Society of Clinicai Oncology Educational B ook. Thirty-third Annual Meeting. Colorado. Asco; 102-4,1997.
Leidich, R.B. - Evaluation and Management of Prostate-Specific Antigen Elevation after Potentially Curati ve Prostate Cancer Therapy. In: American Society of Clinical Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco; 105-10, 1997.
Ravdin, P.M. - The Marker-Positive/Disease-Negative Breast Câncer Patient. In: American Society of Clinical Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco; 111-3,1997.
Garber, J.E. - Breast Câncer Markers: Genetic of Breast Cancer Predisposition. In: American Society of Clinical Oncology Educational Book. Thirty-third Annual Meeting. Colorado. Asco; 213-6,1997.
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Sociedade Brasileira de Urologia. Oncologia HojeN°4-Câncer de Próstata. Rio de Janeiro. Pro-Onco/INCA, 1995. 40 p.il
Ciatto, S. - Breast cancer follow-up: are diagnostic investigations for early detection of distant metastases justified? Oncology in Practice, (3): 15-6, 1996.
Love, S.;Parker, B.;Ames, M.;Taylor, C.; Gilden, R.; Figlin, R. A. - Practice Guidelines for Breast Cancer. The Cancer Journal from Scientific American, 2 (3A), Supp: 7-21, 1996.
Venook, A.; Goodnight, J.; Kumar, S.; Taylor, C.; GiIden, R.; Figlin, R. A. - Practice Guidelines for Colorectal Câncer. The Cancer Journal from Scientific American, 2 (3A), Supp: 23-36, 1996.
American Society of Clinicai Oncology. Clinicai Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer. Journal of Clinical Oncology, 14(10): 2843-77, 1996. DOI: https://doi.org/10.1200/JCO.1996.14.10.2843
_____________. Recommended Breast Câncer Surveillance Guidelines. Journal of Clinical Oncology, 15(5): 2149-56,1997. DOI: https://doi.org/10.1200/JCO.1997.15.5.2149
Ahlering, T.; Parker, R.; Kumar, S.; Taylor, C.; Gilden, R.; Figlin, R. A. - Practice Guidelines for Prostate Câncer. The Cancer Journal From Scientific American, 2(3 A), Supp: 77-86,1996.
